"Open communication with executive level leadership is encouraged & appreciated. Work-life balance is recognized & applauded. People treat one another like family with a sense of pride about ...

Acorda Therapeutics has filed for bankruptcy protection, hoping to keep operating while it tries to arrange the sale of its main assets to a US subsidiary of Germany’s Merz. The announcement ...

It is administered through intramuscular, intradermal and subcutaneous routes. Merz Therapeutics, a subsidiary of Merz Pharma GmbH & Co KgaA, focuses on developing and distributing therapeutic ...

Merz Therapeutics, with North American headquarters in Raleigh, has gained a new use for Xeomin, its botulinum toxin therapy. The U.S. Food and Drug Administration approved Merz’s supplemental ...

Xeomin, a botulinum toxin therapy developed by Raleigh-based Merz Therapeutics, has gained yet another new use. The U.S. Food and Drug Administration approved Merz’s supplemental Biologics License ...

FRANKFURT, Germany--(BUSINESS WIRE)-- Merz Therapeutics, a company of the Merz Group and a leader in the field of neurotoxins, is expanding its strategic partnership with Vensica Therapeutics as ...

Merz Group includes the businesses Merz Aesthetics, Merz Therapeutics, Merz Consumer Care, Merz Real Estate, Merz Financial Investments and Merz Private Markets. The company employs 4,727 people ...

Incobotulinumtoxin A is under clinical development by Merz Therapeutics and currently in Phase II for Unspecified Musculoskeletal Disorders. According to GlobalData, Phase II drugs for Unspecified ...